FDA proposes excluding Novo, Lilly weight loss drugs from bulk compounding list in win for the companies
--------------------------------------------------------------------
Source: CNBC
Published: 2026-05-01 01:02 UTC+10:00
Section: General
Factuality Score: 100
Opinion Category: Neutral
Topics: Health, Food & Agriculture, Drugs, Business & Economy
--------------------------------------------------------------------
Snippet:
The Food and Drug Administration on Thursday proposed excluding the active ingredients in Novo Nordisk and Eli Lilly's blockbuster obesity and diabetes medications from the list of drugs that outsourcing facilities can use for compounding in bulk.
--------------------------------------------------------------------